Bharat Biotech’s Covaxin Vaccine Will Also Be Administered In America, Permission Sought For Children Below 18 Years Of Age 

Bharat Biotech's covaxin
Share this News:

New Delhi, 6th November 2021: Children below 18 years of age in the US may soon receive Bharat Biotech’s Covaxin vaccine. For this, permission has been sought there. US pharma company Ocugen on Friday announced that it has approved the US authorization for emergency use of India-made COVID-19 vaccine Covaxin for children aged 2 to 18 years. 

Covaxin has been developed in India by Bharat Biotech, a partner of Ocugen. This vaccine has received emergency approval from the World Health Organization (WHO) on Wednesday. It has already been approved for use in 17 countries of the world. Millions of doses of this vaccine have been given to adults outside the US, especially in India. 

India Biotech’s partner in the US and Canada, Ocugen Inc, said on Friday that it has applied to the US Food and Drug Administration (FDA) for the use of the vaccine for children for the anti-corona vaccine. Ocugen has told both countries that its application is based on the results of a Phase II-III ‘clinical trial’ conducted in India by Bharat Biotech on 526 children and adolescents aged two to 18 years. 

To know the effectiveness of the vaccine, the results of the third phase conducted on about 25,800 adults in India are also mentioned. Shankar Musunuri, CEO, Co-Founder, and Chairman of the Board, said that applying for emergency use of the vaccine in the US for pediatric use goes a long way towards making the vaccine available and helping combat the COVID-19 pandemic. He said that some studies have suggested that people want more choices in the selection of vaccines for themselves and especially for their children. With the availability of new types of vaccines,